Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BCL2 interacting protein 3 pseudogene 26 (BNIP3P26) is a pseudogene, meaning it is a non-functional segment of DNA similar in sequence to a gene coding for a protein in the BCL2-interacting protein 3 family, but it does not encode a functional protein product. BNIP3P26 is annotated in humans under NCBI Gene ID 100421699 and Ensembl ENSG00000268705. Unlike the functional BNIP3 gene, which is a member of the Bcl-2 family involved in apoptosis and mitochondrial function, BNIP3P26 does not produce an active protein and is not considered a receptor, enzyme, or therapeutic target. There is no known direct disease association or drug interaction for this pseudogene[2][4]. Pseudogenes like BNIP3P26 are generally regarded as non-coding remnants of genes and lack protein-coding potential unless proven otherwise. While some pseudogenes can have regulatory RNA roles, there is currently no evidence for BNIP3P26 functioning as a regulator, biomarker, or therapeutic target[2][4][8]. BNIP3P26 is a non-functional pseudogene, not a drug target, receptor, or enzyme. Any reference to it as a molecule/receptor for therapeutic targeting is incorrect[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BCL2 interacting protein 3 pseudogene 26 (BNIP3P26).